Luxor Scientific, LLC

Luxor Scientific, LLC was paid $5.56M by Medicaid between Jan 2018 and Dec 2024, across 132 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 44% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	14,197	$544K
2019	14,099	$458K
2020	61,103	$574K
2021	23,540	$614K
2022	20,696	$891K
2023	64,745	$1.31M
2024incomplete	48,723	$1.17M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	44%	25,788	17,869	$2.42M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	22%	20,312	15,628	$1.21M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.3%	23,095	16,025	$515K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	7.1%	8,134	7,049	$395K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.8%	1,197	980	$103K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.2%	1,704	1,007	$66K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.2%	653	569	$64K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,715	2,580	$35K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,358	1,201	$31K
87631		<1%	386	338	$27K
80061	Lipid panel	<1%	3,523	3,327	$23K
80053	Comprehensive metabolic panel	<1%	4,236	3,958	$22K

120 more codes

84443	Thyroid stimulating hormone (TSH)	<1%	2,718	$21K
80346		<1%	4,190	$19K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,040	$18K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	4,062	$17K
80364		<1%	4,052	$16K
83970		<1%	907	$16K
80361		<1%	4,210	$16K
84403		<1%	1,338	$15K
82670		<1%	1,199	$15K
84402		<1%	1,185	$13K
84481		<1%	1,528	$13K
82607		<1%	1,774	$12K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	774	$12K
82627		<1%	1,186	$12K
82172		<1%	992	$11K
84146		<1%	1,248	$11K
83992		<1%	4,331	$11K
87529		<1%	308	$10K
84270		<1%	1,038	$10K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	502	$10K
83001		<1%	1,207	$10K
83002		<1%	1,200	$10K
80365		<1%	4,212	$10K
80355		<1%	3,782	$9K
80366		<1%	3,764	$9K
82746		<1%	1,598	$9K
87640		<1%	487	$9K
84144		<1%	1,024	$9K
80349		<1%	2,712	$9K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,533	$9K
80368		<1%	3,225	$9K
80325		<1%	2,784	$9K
80371		<1%	3,077	$8K
87581		<1%	380	$8K
84305		<1%	888	$8K
87486		<1%	373	$8K
86800		<1%	1,019	$8K
80348		<1%	4,209	$7K
80354		<1%	4,207	$7K
80373		<1%	4,206	$7K
80367		<1%	4,204	$7K
80353		<1%	4,207	$7K
80356		<1%	4,206	$7K
80372		<1%	4,203	$7K
80359		<1%	4,148	$7K
80358		<1%	4,206	$7K
86376		<1%	1,040	$7K
82533		<1%	1,027	$7K
86141		<1%	1,118	$7K
80360		<1%	3,576	$7K
86480		<1%	196	$7K
36415	Collection of venous blood by venipuncture	<1%	3,349	$6K
87541		<1%	313	$6K
86038		<1%	1,045	$6K
84439		<1%	1,327	$6K
80352		<1%	1,712	$6K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	418	$5K
80074		<1%	390	$5K
84140		<1%	625	$5K
87532		<1%	260	$5K
84153		<1%	553	$5K
82642		<1%	626	$5K
83540		<1%	1,382	$5K
80370		<1%	2,422	$5K
83735		<1%	1,362	$4K
80369		<1%	1,018	$4K
87088		<1%	640	$4K
83550		<1%	881	$3K
0344U		<1%	250	$3K
87563		<1%	161	$3K
86592		<1%	1,389	$3K
82977		<1%	1,040	$3K
86431		<1%	1,011	$3K
87506		<1%	30	$2K
82728		<1%	307	$2K
84550		<1%	1,049	$2K
80323		<1%	1,357	$2K
87511		<1%	100	$1K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	95	$1K
85652		<1%	1,154	$1K
83090		<1%	1,026	$1K
80338		<1%	998	$1K
80342		<1%	1,230	$834.85
86317		<1%	106	$822.76
87498		<1%	36	$663.90
82248		<1%	248	$656.51
87531		<1%	23	$633.39
87522	Neg quan hep c or qual rna	<1%	96	$613.75
80334		<1%	453	$584.48
80337		<1%	389	$574.66
86039		<1%	98	$537.78
82043		<1%	187	$516.21
80050	General health panel	<1%	79	$500.67
80339		<1%	361	$447.99
80324		<1%	1,287	$380.74
87077		<1%	59	$376.45
87500		<1%	13	$276.74
86803		<1%	44	$258.99
80335		<1%	427	$254.91
84480		<1%	65	$242.85
84436		<1%	370	$225.93
84479		<1%	372	$217.44
87186		<1%	27	$203.46
84681		<1%	15	$171.27
82570		<1%	466	$170.15
86140		<1%	42	$149.94
80048	Basic metabolic panel (calcium, ionized)	<1%	30	$125.90
81001		<1%	74	$124.78
83986		<1%	477	$120.02
80321		<1%	19	$101.93
81003		<1%	475	$89.29
84460		<1%	17	$45.95
85027		<1%	12	$38.84
85610		<1%	32	$30.74
80332		<1%	180	$28.65
84100		<1%	14	$27.77
80350		<1%	221	$15.28
80333		0%	28	$0.00
81596		0%	26	$0.00
80363		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFLANAGAN, JOHN (CEO)